According to the Zhitong Finance App, Zhongke Biotech (01237) announced the 2026 interim results. The group achieved revenue of RMB 242 million during the period, an increase of 21.27% over the previous year; profit attributable to company owners was 15.72 million yuan, an increase of 79.62% over the previous year; and the basic profit per share was 0.1,637 yuan.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.